RS63293B1 - Metabolički biomarkeri za predviđanje reakcije na jedinjenje fgf-18 - Google Patents

Metabolički biomarkeri za predviđanje reakcije na jedinjenje fgf-18

Info

Publication number
RS63293B1
RS63293B1 RS20220558A RSP20220558A RS63293B1 RS 63293 B1 RS63293 B1 RS 63293B1 RS 20220558 A RS20220558 A RS 20220558A RS P20220558 A RSP20220558 A RS P20220558A RS 63293 B1 RS63293 B1 RS 63293B1
Authority
RS
Serbia
Prior art keywords
fgf
treatment
cartilage
compound
subject
Prior art date
Application number
RS20220558A
Other languages
English (en)
Serbian (sr)
Inventor
Christoph H Ladel
Hans Guehring
Anne-Christine Bay-Jensen
Morten Karsdal
Per Qvist
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of RS63293B1 publication Critical patent/RS63293B1/sr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RS20220558A 2017-09-29 2018-09-28 Metabolički biomarkeri za predviđanje reakcije na jedinjenje fgf-18 RS63293B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17194220 2017-09-29
EP18169324 2018-04-25
PCT/EP2018/076395 WO2019063758A1 (en) 2017-09-29 2018-09-28 METABOLIC BIOMARKERS FOR PREDICTING RESPONSE TO FGF-18 COMPOUND
EP18782014.7A EP3687558B1 (en) 2017-09-29 2018-09-28 Metabolic biomarkers for predicting responsiveness to fgf-18 compound

Publications (1)

Publication Number Publication Date
RS63293B1 true RS63293B1 (sr) 2022-06-30

Family

ID=63722380

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220558A RS63293B1 (sr) 2017-09-29 2018-09-28 Metabolički biomarkeri za predviđanje reakcije na jedinjenje fgf-18

Country Status (16)

Country Link
US (2) US11513128B2 (cg-RX-API-DMAC7.html)
EP (1) EP3687558B1 (cg-RX-API-DMAC7.html)
JP (2) JP7791649B2 (cg-RX-API-DMAC7.html)
CN (1) CN111163791A (cg-RX-API-DMAC7.html)
AU (1) AU2018343982B2 (cg-RX-API-DMAC7.html)
CA (1) CA3076029A1 (cg-RX-API-DMAC7.html)
DK (1) DK3687558T3 (cg-RX-API-DMAC7.html)
ES (1) ES2918250T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220760T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058786T2 (cg-RX-API-DMAC7.html)
IL (1) IL273613B2 (cg-RX-API-DMAC7.html)
LT (1) LT3687558T (cg-RX-API-DMAC7.html)
PL (1) PL3687558T3 (cg-RX-API-DMAC7.html)
RS (1) RS63293B1 (cg-RX-API-DMAC7.html)
SI (1) SI3687558T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019063758A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
LT3687558T (lt) 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
IL281333B2 (en) * 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
EP1551426B1 (en) 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
WO2004043237A2 (en) * 2002-11-08 2004-05-27 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
US8224579B2 (en) * 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
US20070292982A1 (en) 2006-06-16 2007-12-20 Jeffery Gail Holloway Method for Manufacturing Transparent Windows in Molded Semiconductor Packages
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
JP2009257842A (ja) * 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
US20100098775A1 (en) 2008-05-02 2010-04-22 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
EP2880179B1 (en) 2012-08-06 2017-12-13 Merck Patent GmbH Genetic markers for predicting responsiveness to fgf-18 compound
PL2880181T3 (pl) 2012-08-06 2019-03-29 Merck Patent Gmbh Biomarkery prognostyczne w zaburzeniach chrząstki
US9829493B2 (en) * 2013-07-15 2017-11-28 Steven J. Svoboda Methods and apparatus for assessment of risk for joint injury
TW201536320A (zh) 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
KR102434024B1 (ko) 2013-12-24 2022-08-22 아레스 트레이딩 에스.아. 알지네이트/콜라겐 히드로겔 중의 fgf-18 제형물
NZ721332A (en) 2013-12-24 2022-07-01 Ares Trading Sa Fgf-18 formulation in xyloglucan gels
ES2698117T3 (es) 2014-02-20 2019-01-31 Merck Patent Gmbh Implante que comprende FGF-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 fgf-18
HRP20181570T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
LT3687558T (lt) * 2017-09-29 2022-06-27 Merck Patent Gmbh Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Also Published As

Publication number Publication date
JP2020535436A (ja) 2020-12-03
US20230251271A1 (en) 2023-08-10
EP3687558A1 (en) 2020-08-05
AU2018343982B2 (en) 2025-03-27
JP7791649B2 (ja) 2025-12-24
IL273613B2 (en) 2026-02-01
LT3687558T (lt) 2022-06-27
HRP20220760T1 (hr) 2022-09-02
DK3687558T3 (da) 2022-06-20
ES2918250T3 (es) 2022-07-14
PL3687558T3 (pl) 2022-07-18
JP2024105273A (ja) 2024-08-06
SI3687558T1 (sl) 2022-08-31
AU2018343982A1 (en) 2020-04-09
IL273613A (en) 2020-05-31
WO2019063758A1 (en) 2019-04-04
IL273613B1 (en) 2025-10-01
US20210231681A1 (en) 2021-07-29
US11513128B2 (en) 2022-11-29
CN111163791A (zh) 2020-05-15
CA3076029A1 (en) 2019-04-04
EP3687558B1 (en) 2022-03-16
US12332251B2 (en) 2025-06-17
HUE058786T2 (hu) 2022-09-28

Similar Documents

Publication Publication Date Title
US12332251B2 (en) Metabolic biomarkers for predicting responsiveness to FGF-18 compound
US12332250B2 (en) Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
US20260102469A1 (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829A (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829B (en) Markers useful in enrichment strategies for the treatment of osteoarthritis